Calliditas Therapeutics AB Annual Research And Development Expense in SEK from 2018 to 2023

Taxonomy & unit: ifrs-full: SEK
Summary: Calliditas Therapeutics AB annual/quarterly Research And Development Expense history and growth rate from 2018 to 2023.
Calliditas Therapeutics AB Research And Development Expense for the quarter ending June 30, 2023 was 89M SEK, a 7.59% decline year-over-year.
Calliditas Therapeutics AB annual Research And Development Expense for 2023 was 502M SEK, a 21.1% increase from 2022.
Calliditas Therapeutics AB annual Research And Development Expense for 2022 was 415M SEK, a 16% increase from 2021.
Calliditas Therapeutics AB annual Research And Development Expense for 2021 was 357M SEK, a 48.1% increase from 2020.

Research And Development Expense, Annual (SEK)

Research And Development Expense, YoY Annual Growth (%)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2023	502M	+87.5M	+21.1%	Jan 1, 2023	Dec 31, 2023	20-F	2024-04-24
2022	415M	+57.3M	+16%	Jan 1, 2022	Dec 31, 2022	20-F	2024-04-24
2021	357M	+116M	+48.1%	Jan 1, 2021	Dec 31, 2021	20-F	2024-04-24
2020	241M	+91.5M	+61.1%	Jan 1, 2020	Dec 31, 2020	20-F	2023-04-26
2019	150M	+50.6M	+50.9%	Jan 1, 2019	Dec 31, 2019	20-F	2022-04-27
2018	99.3M			Jan 1, 2018	Dec 31, 2018	20-F/A	2022-01-14

Showing 1 to 6 of 6 entries

* An asterisk sign (*) next to the value indicates that the value is likely invalid.